Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1868 1
1956 2
1969 1
1973 1
1975 4
1977 4
1978 2
1979 4
1980 6
1981 5
1982 7
1983 4
1984 6
1985 14
1986 10
1987 11
1988 12
1989 11
1990 9
1991 12
1992 10
1993 9
1994 24
1995 17
1996 13
1997 13
1998 4
1999 18
2000 22
2001 28
2002 23
2003 21
2004 18
2005 27
2006 15
2007 31
2008 14
2009 14
2010 15
2011 11
2012 8
2013 9
2014 11
2015 13
2016 12
2017 14
2018 15
2019 20
2020 16
2021 15
2022 21
2023 31
2024 27
2025 17

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

666 results

Results by year

Filters applied: . Clear all
Page 1
Teclistamab in Relapsed or Refractory Multiple Myeloma.
Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Nooka AK, Martin T, Rosinol L, Chari A, Karlin L, Benboubker L, Mateos MV, Bahlis N, Popat R, Besemer B, Martínez-López J, Sidana S, Delforge M, Pei L, Trancucci D, Verona R, Girgis S, Lin SXW, Olyslager Y, Jaffe M, Uhlar C, Stephenson T, Van Rampelbergh R, Banerjee A, Goldberg JD, Kobos R, Krishnan A, Usmani SZ. Moreau P, et al. Among authors: stephenson t. N Engl J Med. 2022 Aug 11;387(6):495-505. doi: 10.1056/NEJMoa2203478. Epub 2022 Jun 5. N Engl J Med. 2022. PMID: 35661166 Free PMC article. Clinical Trial.
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
Usmani SZ, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Rosinol L, Chari A, Bhutani M, Karlin L, Benboubker L, Pei L, Verona R, Girgis S, Stephenson T, Elsayed Y, Infante J, Goldberg JD, Banerjee A, Mateos MV, Krishnan A. Usmani SZ, et al. Among authors: stephenson t. Lancet. 2021 Aug 21;398(10301):665-674. doi: 10.1016/S0140-6736(21)01338-6. Epub 2021 Aug 10. Lancet. 2021. PMID: 34388396 Clinical Trial.
Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study.
Cortes-Selva D, Perova T, Skerget S, Vishwamitra D, Stein S, Boominathan R, Lau O, Calara-Nielsen K, Davis C, Patel J, Banerjee A, Stephenson T, Uhlar C, Kobos R, Goldberg J, Pei L, Trancucci D, Girgis S, Wang Lin SX, Wu LS, Moreau P, Usmani SZ, Bahlis NJ, van de Donk NWCJ, Verona RI. Cortes-Selva D, et al. Among authors: stephenson t. Blood. 2024 Aug 8;144(6):615-628. doi: 10.1182/blood.2023022823. Blood. 2024. PMID: 38657201 Free PMC article. Clinical Trial.
Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation.
Frerichs KA, Verkleij CPM, Mateos MV, Martin TG, Rodriguez C, Nooka A, Banerjee A, Chastain K, Perales-Puchalt A, Stephenson T, Uhlar C, Kobos R, van der Holt B, Kruyswijk S, Kuipers MT, Groen K, Vishwamitra D, Skerget S, Cortes-Selva D, Doyle M, Zaaijer HL, Zweegman S, Verona RI, van de Donk NWCJ. Frerichs KA, et al. Among authors: stephenson t. Blood Adv. 2024 Jan 9;8(1):194-206. doi: 10.1182/bloodadvances.2023011658. Blood Adv. 2024. PMID: 38052042 Free PMC article.
Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1.
Miao X, Wu LS, Lin SXW, Xu Y, Chen Y, Iwaki Y, Kobos R, Stephenson T, Kemmerer K, Uhlar CM, Banerjee A, Goldberg JD, Trancucci D, Apte A, Verona R, Pei L, Desai R, Hickey K, Su Y, Ouellet D, Samtani MN, Guo Y, Garfall AL, Krishnan A, Usmani SZ, Zhou H, Girgis S. Miao X, et al. Among authors: stephenson t. Target Oncol. 2023 Sep;18(5):667-684. doi: 10.1007/s11523-023-00989-z. Epub 2023 Sep 15. Target Oncol. 2023. PMID: 37713090 Free PMC article.
Shedding light on non-accidental bruising.
Stephenson T. Stephenson T. Arch Dis Child. 2015 May;100(5):419-20. doi: 10.1136/archdischild-2014-307869. Epub 2015 Feb 4. Arch Dis Child. 2015. PMID: 25653224 No abstract available.
Long COVID in children and adolescents.
Stephenson T, Shafran R, Ladhani SN. Stephenson T, et al. Curr Opin Infect Dis. 2022 Oct 1;35(5):461-467. doi: 10.1097/QCO.0000000000000854. Epub 2022 Aug 3. Curr Opin Infect Dis. 2022. PMID: 36098262 Free PMC article.
Chemical editing of proteoglycan architecture.
O'Leary TR, Critcher M, Stephenson TN, Yang X, Hassan AA, Bartfield NM, Hawkins R, Huang ML. O'Leary TR, et al. Among authors: stephenson tn. Nat Chem Biol. 2022 Jun;18(6):634-642. doi: 10.1038/s41589-022-01023-5. Epub 2022 May 12. Nat Chem Biol. 2022. PMID: 35551261 Free PMC article.
Dr Dennis Cotton 1939-2019.
Cross S, Stephenson T, Underwood J. Cross S, et al. Among authors: stephenson t. Histopathology. 2019 Oct;75(4):613. doi: 10.1111/his.13896. Histopathology. 2019. PMID: 31069836 No abstract available.
666 results